作者:Peng, Feng、Qi, Ji、Zhang, Jin、Wang, Enkai、Cao, Xiaohui、Chen, Lu、Fan, Chao、Fan, Wei、Feng, Cheng、Lin, Mingxiang、Liu, Mingjie、Nawrat, Christopher C.、Schultz, Danielle M.、Song, Chaohui、Wang, Feng、Yin, Jingjun、Zhang, Yuming
DOI:10.1021/acs.oprd.4c00003
日期:——
MK-7845 was designed as a 3C-like protease inhibitor for the treatment of COVID-19. To enable a rapid kilo-scale delivery of MK-7845 to accelerate its First-in-Human studies, we developed a fit-for-purpose process to produce two key building blocks in less than two months. The key discoveries were a highly diastereoselective Ellman addition route for β-aminoamide 6 and crystallization isolation methods
MK-7845 被设计为一种类 3C 蛋白酶抑制剂,用于治疗 COVID-19。为了能够快速交付公斤级的 MK-7845,以加速其首次人体研究,我们开发了一种适合用途的工艺,可在不到两个月的时间内生产出两个关键的构建模块。关键发现是β-氨基酰胺6的高度非对映选择性埃尔曼加成路线以及在良好质量控制下生产6和酸9的结晶分离方法。